Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014)

Zevra Therapeutics (ZVRA) posted Preferred Stock Liabilities of $24.2 million for Q4 2014.

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014) Analysis & Trends

Zevra Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $24.2 million for Q4 2014.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $24.2 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $24.2 million (changed N/A YoY) and the FY2014 annual result came in at $24.2 million, up 30.51% from the prior year.
Preferred Stock Liabilities was $24.2 million for Q4 2014 at Zevra Therapeutics.
Across five years, Preferred Stock Liabilities topped out at $24.2 million in Q4 2014 and bottomed at $24.2 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Zevra Therapeutics	239.71 Mn	39.10 Mn	34.32 Mn	-

Download Data

Date	Value
Dec 31, 2014	24.21 Mn